First‐in‐Asian Phase I Study of the Anti‐Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X‐linked Hypophosphatemia

X‐linked hypophosphatemia (XLH) is a disease caused by abnormally elevated FGF23 levels, which cause persistent hypophosphatemia accompanied by subsequent reduction in bone mineralization that presents as rickets or osteomalacia. Burosumab is a fully human monoclonal antibody targeting FGF23 that is...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheong, Hae Il, Yoo, Han‐Wook, Adachi, Masanori, Tanaka, Hiroyuki, Fujiwara, Ikuma, Hasegawa, Yukihiro, Harada, Daisuke, Sugimoto, Maiko, Okada, Yosuke, Kato, Masaki, Shimazaki, Ryutaro, Ozono, Keiichi, Seino, Yoshiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383703/
https://www.ncbi.nlm.nih.gov/pubmed/30828689
http://dx.doi.org/10.1002/jbm4.10074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383703/
https://www.ncbi.nlm.nih.gov/pubmed/30828689
http://dx.doi.org/10.1002/jbm4.10074

Ejemplares similares